Kenya malaria vaccine, first in the world

Image result for vaccination kenya

Kenya will be the first country in the world to introduce the malaria vaccine in March 2019.

At least 120,000 children are expected to get the vaccine in select hospitals in Kakamega, Vihiga, Bungoma, Busia, Kisumu, Homa Bay, Migori and Siaya counties.

The vaccine Mosquirix will be given to children aged six months to 24 months in four doses.

The four doses will be administered at six, seven, nine and 24 months through an injection on the upper arm.

A child gets the RTS,S malaria vaccine during the clinical trials. / FILE

The Ministry of Health is expected to formally make the announcement soon.

Details of the expected roll-out emerged in a stakeholders meeting organised in Nairobi by the ministry yesterday.

The pilot roll-out will assess the feasibility of delivering four doses in real-life settings, and assess the vaccine’s potential to reduce child deaths.

The pilot has faced various delays as it was first scheduled for October 2018.

Image result for vaccination kenya

“We may have been over-optimistic with the timelines,” David Schellenberg, scientific adviser to the World Health Organization’s Global Malaria Programme, said recently.

WHO is supporting the introduction of the vaccine in Kenya, Ghana and Malawi.

The pilot will be complete by 2021, but researchers will continue monitoring feasibility and safety until 2022.

The results will help Kenya decide whether or not to adopt the vaccine and make it part of routine immunisation.

Image result for health ministry kenya

Last year, head of malaria control Ejersa Waqo said the children will still need to take the usual malaria control precautions such as sleeping under mosquito nets.

Currently, treated mosquito nets and residual spraying are among the major interventions being used to reduce prevalence.

Three major donors are partnering to provide Sh5 billion for the first phase of the vaccine pilot in the three countries.

Image result for health ministry kenya

Mosquirix, also called RTS,S, was first conceived in the 1980s and has undergone all clinical trials, returning less than optimal results.

The vaccine – made by GSK – is only effective in 30 to 50 per cent of patients, says the WHO.

Leave a Reply

Your email address will not be published. Required fields are marked *